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A Small Molecule Drug Conjugate (SMDC) of DUPA and a 
Duocarmycin Built on the Solid Phase 
Andrew Michael Beekman,*a Marco M. D. Cominetti,a Oliver Charles Cartwright,a Dale L. Bogerb and 
Mark Searcey*ac 
In a proof-of-concept study, solid phase synthesis allowed the rapid generation of a small molecule drug conjugate in which 
the glutamate carboxypeptidase II (GCPII) targeting small molecule DUPA was conjugated to the alkylating subunit of the 
potent cytotoxin duocarmycin SA. The doubly targeted SMDC contained a cathepsin B cleavable linker, which was shown to 
be active and selective against cathepsin B over-expressing and GCPII-expressing tumour cell lines.
Introduction 
Targeted cancer therapy is among the most promising 
strategies for the realisation of side effect free oncology 
treatment.1 The development of precision medicine will allow 
promising cytotoxic moieties that are already known to be 
delivered to specific sites of action.2 
Small molecule drug conjugates (SMDCs) present an exciting 
technique to harness the potential of cytotoxic compounds that 
demonstrate therapeutic windows too small for clinical use.3,4 
Small molecules that target receptors or antigens 
overexpressed in cancers may not be useful as treatments for 
these disease states in themselves, but, in conjunction with 
ultrapotent cytotoxins, a symbiotic partnership is generated to 
act as a viable solution. SMDCs offer advantages over antibody 
drug conjugates (ADCs) and peptide drug conjugates (PDCs). 
SMDCs are inexpensive, completely characterised, readily 
tuneable and non-immunogenic.3  Additionally, as the name 
suggests, SMDCs are small, low molecular weight conjugates, 
benefitting cell permeability in solid tumours and stability.4 This 
concept has been championed by the use of folate, with the vast 
majority of SMDCs exploiting this efficient directing group.2-4 
However, several other examples exist which target the fusion 
protein BCR/ABL, aminopeptidase N and glutamate 
carboxypeptidase II (GCPII), among others. 
 
GCPII, also known as prostate specific membrane antigen 
(PSMA), N-acetyl-α-linked acidic dipeptidase I (Naaladase I) or 
folate hydrolase (FOLH1), is over expressed in almost all 
prostate cancers, as well as several other cancer lines.5 GCPII 
expression in cancerous cells is approximately 1000-fold more 
than healthy tissue.6 Once a ligand is bound, GCPII undergoes 
endocytosis, unloading the ligand, and recycling back to the cell 
surface.7 These factors highlight GCPII as an excellent candidate 
for tumour-targeted drug delivery.8-10 Its importance as a 
diagnostic and therapeutic target have resulted in extensive 
study into inhibitors of GCPII, with several potent and selective 
compounds identified.11 2-[3-(1,3- dicarboxypropyl)ureido]-
pentanedioic acid (DUPA, 1, Figure 1) has a high affinity for 
GCPII (Ki = 8 nM),12-14 and has been widely exploited for 
diagnostics. Studies demonstrated that DUPA-linked cytotoxic 
drugs such as tubulysin B hydrazide and desacetyl vinblastine 
hydrazide are able to eradicate tumours in vivo and eliminate 
nonspecific toxicity associated with the unconjugated drugs.9 
 
Figure 1. Structures of GCPII ligand DUPA, 1 (2-[3-(1,3- 
dicarboxypropyl)ureido]pentanedioic acid) and duocarmycin synthetic unit Fmoc-
DSA(OBn)-OH, 2. 
 
The duocarmycins are a family of DNA-alkylating natural 
products that demonstrate ultrapotent cytotoxic activity.15,16 
Despite several clinical trials and implementation in a number 
of antibody drug conjugates, the duocarmycins are yet to reach 
the market. Work by Neri and co-workers demonstrated the 
applicability of duocarmycin payloads to SMDCs, attaching a 
modified CBI unit to a carbonic anhydrase IX (CAIX) targeting 
ligand.17 However, the use of the duocarmycins in SMDCs has 
been limited to this proof-of-concept work. With our recent 
development of a duocarmycin payload ready for solid phase 
peptide synthesis (SPPS),18 Fmoc-DSA(OBn)-OH (2, Figure 1), 
this family of cytotoxins is poised for implementation in all 
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directing strategies. SMDCs have resulted in a number of 
compounds entering clinical trials, most of which exploit folate 
as a directing small molecule.3,4 We disclose here a proof-of-
concept study demonstrating a duocarmycin alkylating unit 
directed by the GCPII targeting ligand DUPA, built on the solid 
phase. Additionally, the implementation of a cathepsin B 
enzyme cleavable sequence provides a secondary directing 
method, demonstrating the duocarmycins have high potential 
for SMDCs. 
Results and Discussion 
 
Figure 2. Duocarmycin DUPA small molecule drug conjugate structure, 3. 
SMDCs are typically made up of the targeting small molecule, a 
spacer, a linker – often cleavable – and finally the warhead. In 
an exhibition of the utility of the Fmoc-DSA(OBn)-OH unit the 
design of our SMDC (3, Figure 2) focussed on the ability to be 
synthesised on the solid phase. We have demonstrated 
previously that a neutral C-terminus is required for the activity 
of the Fmoc-DSA-OH unit,18 and as such synthesis on Rink amide 
resin was selected to provide a terminal amide. The racemic 
duocarmycin was employed to allow the proof-of-concept to be 
demonstrated with synthetic ease, balancing the likely sacrifice 
of activity.19 The routinely employed PABA-Cit-Val cathepsin B 
enzyme cleavable sequence was chosen as both the spacer and 
linker for two reasons. Firstly, the secondary targeting effect, 
with cathepsin B being overexpressed in cancer cell lines.20,21 
Secondly, the para-aminobenzoic acid (PABA) unit can also act 
as a DNA binding unit.22 The synthetic ease and availability of 
Fmoc-PABA-OH made it more attractive for this proof-of-
concept study compared to, say, an indole unit – more 
reminiscent of the natural products – despite the known 
reduction in efficacy. Finally, the GCPII binding ligand 2-[3-(1,3- 
dicarboxypropyl)ureido]pentanedioic acid (DUPA, 1)  was 
chosen as a directing group because of its high affinity for GCPII 
(Ki = 8 nM) and the carboxylic acid handle readily obtained via 
the synthesis described by Cushman and co-workers.14 The tri-
tbutyl protected DUPA was prepared as previously described 
(Scheme 1).14 Briefly, α,γ-di-tert-butyl glutamate 4 was treated 
with triphosgene and Et3N, followed by addition of glutamate 5, 
with benzyl protection on the γ-carboxylate and a tbutyl 
protecting group on the α-carboxylate, provided protected 
DUPA 6. Hydrogenation with Pd/C under a hydrogen 
atmosphere yielded tri-tbutyl protected DUPA 7.10,13  
 
Scheme 1. Synthesis of tri-tbutyl protected DUPA as reported by Cushman and co-workers.14 Solid phase synthesis of the DSA DUPA small molecule drug conjugate. Payload 
duocarmycin 8. 
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Synthesis of the SMDC began with the loading of Fmoc-
DSA(OBn)-OH, 1 onto rink amide resin (Scheme 1). Coupling was 
achieved with HOBt and HBTU in the presence of DIPEA over 24 
hours. These conditions allow for complete coupling, with only 
1.2 equivalents of the Fmoc-DSA(OBn)-OH unit. Subsequently, 
Fmoc solid phase peptide synthesis techniques were routinely 
employed to add first Fmoc-PABA-OH, followed by Fmoc-Cit-OH 
and Fmoc-Val-OH. Removal of the final Fmoc protecting group 
provided a terminal amine which was then coupled using the 
same amide coupling conditions to the appropriately protected 
DUPA unit 7. Cleavage from the resin and deprotection was 
achieved with a cleavage cocktail of 95% trifluoroacetic acid 
(TFA), 2.5% triisopropylsilane (TIPS) and 2.5% water. Following 
evaporation and trituration with diethyl ether the crude peptide 
was debenzylated using H2/Pd-C to provide the liberated DSA 
phenolic OH. Purification was achieved with reverse phase 
preparative HPLC, providing the desired SMDC 3. The analogous 
process was employed, terminating at the addition of Fmoc-
PABA-OH, with subsequent deprotection, cleavage and benzyl 
deprotection to generate the payload 8 (Scheme 1). 
With the desired construct obtained, evaluation of the ability of 
DUPA to direct and harness the potent activity of the 
duocarmycins could be evaluated. Commonly, when GCPII is 
being examined in prostate cancer, the cell lines LNCaP (GCPII 
positive) and PC3 (GCPII negative) are employed.23,24 To extend 
the applicability of this proof-of-concept further we examined 
the SMDC in lung cancer cell lines H292 and A549, breast cancer 
cell lines MCF-7 and SKBR3 and melanoma cell line SKMEL28. 
The non-cancerous cell line 16HBE14o was used as a control. 
Each of the cell lines was analysed using flow cytometry to 
evaluate the expression of GCPII. 16HBE14o and PC3 showed no 
expression of GCPII and LNCaP demonstrated high levels of 
GCPII. Additionally, H292, A549, MCF-7, and SKMEL28 also 
demonstrated elevated expression of GCPII. SKBR3 
demonstrated a slightly reduced expression of GCPII (See SI). All 
cell lines were examined for their cathepsin B activity using a Z-
Arg-Arg-7-amido-4-methylcoumarin hydrochloride (Z-RR-AMC) 
assay. The ability to cleave the Arg-Arg sequence and release 
the fluorescent amino-4-methylcoumarin was compared to the 
noncancerous cell line 16HBE14o. All cancer cells lines 
demonstrated increased cathepsin B activity, while 16HBE14o 
demonstrated no appreciable cathepsin B activity (See SI). Each 
of the cell lines were then evaluated in an MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) cell viability assay (Table 1). The 
SMDC (3), the benzyl-protected DSA version (3-OBn), as well as 
the enzyme cleaved payload (8) were incubated with cell 
cultures for 72 hours, followed by treatment with MTS. All cell 
lines demonstrated sensitivity to the precleaved PABA-DSA 
payload 8 in the nanomolar range. Cell lines which 
demonstrated high GCPII expression and cathepsin B activity 
had IC50 values at high nanomolar concentrations when treated 
with 3. Excitingly, SKBR3 cells, which showed reduced GCPII 
expression, demonstrated correspondingly weaker compound 
3 efficacy. Additionally, PC3 cells, which are GCPII negative but 
showed high cathepsin B activity, demonstrated an IC50 greater 
than 100 µM, indicating GCPII plays a key role in the activity of 
the SMDC. The non-cancerous cell line 16HBE14o which 
demonstrated no GCPII expression, and no appreciable 
cathepsin B activity also showed no sensitivity to the SMDC. The 
benzyl-protected DSA SMDC (3-OBn) demonstrated no toxicity 
to cell lines at 100 µM, suggesting DNA alkylation is responsible 
for the SMDC’s efficacy. 
Table 1: IC50 results obtained for compounds 3, 3-OBn and 8 to selected cancerous and 
non-cancerous cell lines. Errors are 95% confidence intervals. 












































To provide evidence that GCPII is responsible for the activity of 
the SMDC a competition assay was employed. LNCaP and PC3 
cells were incubated with the known GCPII inhibitor 2-
(phosphonomethyl)-pentandioic acid (2-PMPA)25 at 10 µM 
before treatment with the DUPA-DSA SMDC and the payload 
PABA-DSA. Cell viability was determined with the MTS assay 
(Figure 3). As expected treatment with 8 in the presence of 2-
PMPA demonstrated no significant change (PC3 cells IC50 = 6.1 
nM [5.2; 7.1], LNCaP cells IC50 = 25.5 nM [17.7; 36.5]), nor 3 in 
the presence of 2-PMPA to PC3 cells (IC50 > 100 µM). However, 
the efficacy of 3 to the GCPII overexpressing LNCaP was greatly 
diminished by the presence of 2-PMPA (IC50 > 100 µM), 
suggesting GCPII is not available for binding, weakening the 
ability of the SMDC to enter cells. 
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Figure 3. Competitive binding antiproliferation assay of SMDC 3 and payload 8, 
in the absence of GCPII binder 2-PMPA, or in the presence of 2-PMPA (10 µM). 
Y-axis is the normalised absorbance at 490 nm after treatment with MTS for 3 hr. 
Results are representative of three independent experiments. 
 
Conclusions 
This proof-of-concept study has provided new insight into 
harnessing the ultrapotent duocarmycin family. Employing the 
low nanomolar GCPII binding DUPA molecule has allowed for 
the targeting of an important oncological target. The use of a 
cathepsin B enzyme cleavable sequence has imparted a 
secondary targeting effect, further directing the payload to 
cancerous cells. The SMDC employing a duocarmycin alkylating 
unit had demonstrated nanomolar IC50 values to cell lines which 
express GCPII and overexpress cathepsin B, but show no 
appreciable toxicity to cell lines which do not express GCPII. 
Additionally, levels of expression correlate to the toxicity of the 
SMDC. Excitingly, cell lines which do not express GCPII and do 
not demonstrate overexpression of cathepsin B demonstrated 
no sensitivity to the SMDC, despite low nanomolar IC50 for the 
DSA-PABA warhead. The SMDCs efficacy appears to be reliant 
on GCPII, with a competition assay greatly reducing the efficacy 
of the SMDC to overexpressing LNCaP cells. This work suggests 
that the duocarmycins are suitable payloads for small molecule 
drug conjugates, and that they can be readily and rapidly 
produced on the solid phase. Work continues to improve the 
toxicity of the payload while maintaining the excellent directing 
nature of the conjugate. 
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